Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation study of JRF103 tablets in advanced solid tumors
CTR20210232Phase 2Active
- Sponsor
- Chengdu Jinruijiye Biotechnology
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JRF103 in Nonhematologic neoplasms, sponsored by Chengdu Jinruijiye Biotechnology. Started Jun 2021; status: active.
02
Drugs
JRF103
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20210232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210232.